Detection of Aneuploidy in Cell Free DNA to Improve the Sensitivity of Diagnostic Peritoneal Lavage in Gastric Cancer - Trial NCT06308510
Access comprehensive clinical trial information for NCT06308510 through Pure Global AI's free database. This phase not specified trial is sponsored by Erasmus Medical Center and is currently Not yet recruiting. The study focuses on Gastric Cancer. Target enrollment is 63 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Erasmus Medical Center
Timeline & Enrollment
N/A
Jul 01, 2024
Jul 01, 2028
Primary Outcome
Sensitivity mFast-SeqS
Summary
Aneuploidy may be used as a more sensitive diagnostic tool to detect peritoneal metastasis
 compared to conventional cytology and imaging techniques. Our aim is to establish whether
 aneuploidy as detected in cfDNA (as a measure for ctDNA) in PLF of patients with GC may hold
 value as an additional staging and tumor evaluation method in GC patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06308510
Non-Device Trial